Last reviewed · How we verify
Oracea
At a glance
| Generic name | Oracea |
|---|---|
| Also known as | doxycycline USP, 40 mg (30 mg immediate release/ 10 mg delayed release beads) |
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Doxycycline Use in Post-Operative Seromas (PHASE2)
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity (PHASE1)
- The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (NA)
- Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF) (NA)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oracea CI brief — competitive landscape report
- Oracea updates RSS · CI watch RSS
- Galderma R&D portfolio CI